GHK-Cu

What it is

GHK-Cu is a small copper-binding peptide complex first associated with tissue-remodeling biology in the 1970s. The peptide portion, GHK, consists of glycine, histidine, and lysine. It binds copper(II) with high affinity and is commonly referred to in cosmetic ingredient labeling as Copper Tripeptide-1 or prezatide copper^{[1 ,7 ]}. In research literature, GHK has been described in human plasma, saliva, and urine, with some reviews reporting lower plasma concentrations in older adults than in young adults^{[7 –8 ]}.

Biological rationale

The compound’s biological interest comes from two overlapping concepts. First, copper is an essential cofactor in enzymes involved in connective tissue formation, oxidative-stress defense, and normal cellular metabolism. Second, GHK appears to interact with fibroblast, extracellular matrix, and wound-repair pathways in cell culture and animal models^{[7 –10 ]}. This does not mean that applying or injecting GHK-Cu broadly “reverses aging.” It means that specific biological signals relevant to collagen synthesis, matrix remodeling, inflammation, and repair have been investigated in defined experimental systems.

Cosmetic versus drug positioning

GHK-Cu is most familiar to consumers as a topical cosmetic ingredient in serums and creams marketed for visible skin aging. Under FDA’s cosmetics framework, products intended only to cleanse, beautify, promote attractiveness, or alter appearance are regulated as cosmetics, and cosmetic ingredients generally do not require FDA premarket approval, except for color additives^{[2 –3 ]}. However, FDA states that products intended to treat disease or affect the structure or function of the body are drugs, even if they also affect appearance^{[3 –4 ]}. This distinction matters for copper-peptide claims: “improves the appearance of fine lines” is materially different from “heals wounds,” “regenerates tissue,” or “treats hair loss.”

Routes studied

When used in research or clinical studies, GHK-Cu has most often been studied topically, including topical gel or cream formulations. A multicenter randomized study in diabetic neuropathic ulcers evaluated a topical GHK-Cu gel under standardized wound-care conditions^{[11 ]}. Cosmetic studies have evaluated facial or periocular creams in photoaged skin, though some of that literature is in conference proceedings or cosmetic-science publications rather than large, independently replicated dermatology trials^{[8 ,12 –14 ]}. Injectable use is a different category: public biohacking discussion often treats injected GHK-Cu as an “anti-aging” or “recovery” peptide, but published human evidence for injectable GHK-Cu is not comparable to the topical literature.

Regulatory status

GHK-Cu is not approved by FDA as a drug for any medical indication. No FDA-approved prescription product for GHK-Cu was identified in the sources reviewed for this draft. The FDA Substance Registration System / UNII record establishes a substance identity for prezatide copper, but FDA explicitly cautions that UNII availability does not imply regulatory review or approval^{[1 ]}.

Cosmetic vs. drug — the FDA framework

Topical cosmetic products containing Copper Tripeptide-1 occupy a different regulatory lane from drugs. FDA explains that cosmetic products and ingredients generally do not require FDA premarket approval, except color additives, but companies remain responsible for product safety and labeling^{[2 ]}. FDA also states that intended use determines whether a product is a cosmetic, a drug, or both; claims to treat disease or affect the structure or function of the body can make a product a drug^{[3 –4 ]}. For ProPeptideGuide editorial purposes, the safest framing is: cosmetic topical GHK-Cu may be lawfully sold when marketed with cosmetic claims, but GHK-Cu is not an FDA-approved treatment for wrinkles, wounds, hair loss, inflammation, or systemic “regeneration.”

Compounding policy

Compounding status is more restrictive than many consumer-facing peptide pages suggest. FDA’s general compounding guidance states that section 503A compounders may use a bulk drug substance only if it meets a USP/NF monograph, is a component of an FDA-approved drug product, or appears on FDA’s 503A bulks list; section 503B outsourcing facilities may use a bulk substance only if it appears on the 503B bulks list or the compounded drug appears on FDA’s drug shortage list at the relevant time^{[5 –6 ]}. In FDA’s April 22, 2026 503A update, “GHK-Cu (except for injectable routes of administration)” was removed from Category 1 because nominations were withdrawn, and “GHK-Cu (for injectable routes of administration)” was removed from Category 2 for the same reason; FDA stated it intends to consult the Pharmacy Compounding Advisory Committee before the end of February 2027 regarding potential inclusion of GHK-Cu on the 503A bulks list^{[5 ]}. Removal from the interim nomination categories is not FDA approval and should not be interpreted as a green light for patient-use compounding.

FDA also lists prior safety concerns for injectable GHK-Cu, stating that compounded injectable drugs containing GHK-Cu may pose immunogenicity risks related to aggregation and peptide-related impurities, and that human safety data are limited^{[15 ]}. GHK-Cu is not listed as a controlled substance in the federal schedules in 21 CFR Part 1308 as reviewed on May 5, 2026, but lack of DEA scheduling does not make an unapproved drug product lawful to market or prescribe^{[16 ]}.

Internationally, GHK-Cu is widely used as a cosmetic ingredient, but no major FDA-equivalent drug approval for systemic or injectable therapeutic use was confirmed for this draft. Last regulatory verification: May 5, 2026.

Research summary

The most defensible human evidence for GHK-Cu is topical and dermatologic, not injectable or systemic.

Diabetic neuropathic ulcers — Mulder 1994

In a multicenter randomized, evaluator-blinded, placebo-controlled trial published in 1994, Mulder and colleagues studied topical glycyl-L-histidyl-L-lysine copper complex gel in diabetic neuropathic ulcers as part of standardized wound care. The abstract reports greater median plantar-ulcer area closure with active gel than vehicle and a lower incidence of ulcer infections in ulcers treated immediately after debridement^{[11 ]}. This is clinically relevant but should be interpreted in context: it is an older study, it evaluated a topical wound product under structured wound care, and it did not establish modern broad claims for cosmetic anti-aging or injectable use.

Cosmetic photoaging studies

Cosmetic and photoaging studies have reported improvements in visible skin parameters, but the evidence base is mixed in format and rigor. A 2018 review by Pickart and Margolina summarizes studies in women with photoaged skin, including a 12-week facial cream study in 71 women, an eye-cream study in 41 women, and biopsy-based comparisons of topical GHK-Cu with vitamin C or retinoic acid^{[8 ,12 –14 ]}. These reports support why Copper Tripeptide-1 became a common cosmetic ingredient, but several cited studies are conference abstracts, book chapters, or cosmetic-science publications rather than large independent randomized trials in major dermatology journals. The strongest editorial wording is that topical GHK-Cu has been studied for visible signs of skin aging — not that it is proven to treat skin aging as a medical condition.

Mechanistic and preclinical models

Mechanistic research supports biological plausibility. In fibroblast and wound-related models, GHK-Cu has been reported to affect collagen synthesis, glycosaminoglycan synthesis, matrix metalloproteinases, and tissue-remodeling pathways^{[8 –10 ]}. Maquart and colleagues reported in vivo stimulation of connective-tissue accumulation in rat experimental wounds, while Siméon and colleagues studied modulation of glycosaminoglycans, proteoglycans, and metalloproteinases in wound models^{[9 –10 ,17 ]}. These findings are mechanistic and preclinical; they cannot be directly translated into human claims about injectable or systemic outcomes.

Lung-injury and COPD literature — overinterpreted online

The COPD and lung-injury literature is especially prone to overinterpretation online. Campbell and colleagues used gene-expression signatures from emphysema-related lung destruction and identified GHK as a compound that could reverse aspects of a disease-associated expression pattern in computational and cell-based analyses; COPD fibroblast function was also evaluated in vitro^{[18 ]}. Later preclinical studies examined GHK-Cu in cigarette-smoke-related skeletal muscle dysfunction and silicosis/lung-fibrosis models^{[19 –20 ]}. These studies are scientifically interesting, but they do not establish GHK-Cu as a treatment for COPD, lung fibrosis, muscle loss, or systemic aging in humans.

Hair-related research

Hair-related claims are also weaker than cosmetic marketing often implies. A frequently cited copper-peptide hair study evaluated AHK-Cu, a related alanine-histidine-lysine copper complex, in human hair follicles ex vivo and dermal papilla cells in vitro^{[21 ]}. That study is relevant to the broader copper-tripeptide category but is not a clinical trial of GHK-Cu for androgenetic alopecia or hair loss. As of this review, no large, well-controlled human clinical trial was identified showing that GHK-Cu treats hair loss.

Ongoing trials

A Phase 2 trial record posted in 2026 describes topical GHK-Cu gel for standardized acute punch-biopsy wounds in healthy adults, with estimated enrollment of 60 and primary completion estimated in 2027^{[22 ]}. Because this trial is recruiting and has no posted results as of May 5, 2026, it should be cited only as evidence of ongoing investigation, not efficacy.

Where the evidence ends

The evidence quality is route-specific. Topical GHK-Cu has limited but plausible human data in cosmetic-skin and wound contexts. Injectable GHK-Cu has substantial public attention but lacks the clinical evidence base needed to support therapeutic, systemic anti-aging, recovery, or hair-growth claims.

Public discourse

Marisa Garshick, MD, board-certified dermatologist, described copper peptides in Vogue in the context of topical skincare and visible aging, emphasizing their role as carrier peptides^{[23 ]}.

Whitney Hovenic, MD, dermatologist and Mohs surgeon, framed the cosmetic dermatology evidence in Women’s Health as promising but not equivalent to retinoids or vitamin C^{[24 ]}.

Ava Shamban, MD, dermatologist, discussed GHK-Cu in The Cut as a carrier peptide and noted formulation limitations^{[25 ]}.

Amanda Kahn, MD, internist and longevity physician, discussed injectable GHK-Cu in longevity practice while acknowledging the evidence boundary. This statement should be interpreted as commentary, not as evidence that injectable GHK-Cu is FDA-approved or legally compoundable^{[25 ]}.

Public discourse reflects the views of the speakers cited and does not represent medical advice or the editorial position of ProPeptideGuide.

Side effects and safety

For topical cosmetic use, reported and plausible adverse effects include local irritation, redness, stinging, pruritus, contact dermatitis, and sensitivity to formulation excipients. FDA cosmetics rules place responsibility for cosmetic product safety and labeling on manufacturers, and cosmetic products do not undergo the same premarket approval process as drugs^{[2 ]}. People may also react differently to copper-peptide products depending on concentration, vehicle, barrier integrity, and concurrent use of acidic or irritating topical ingredients.

Wound-care context

In clinical wound research, topical GHK-Cu was studied under controlled wound-care conditions; the 1994 diabetic ulcer trial reported outcomes including infection incidence, but that does not establish broad over-the-counter safety for open wounds or post-procedure use outside supervised care^{[11 ]}. Wound care is a medical context, and product sterility, diagnosis, debridement, offloading, infection control, and underlying disease status can materially affect safety and outcomes.

Injectable safety concerns

Injectable GHK-Cu raises a different set of concerns. FDA has specifically identified potential immunogenicity risks for compounded injectable GHK-Cu related to aggregation and peptide-related impurities, and noted limited human data to inform safety considerations^{[15 ]}. Unapproved injectable products also carry general risks related to sterility, endotoxin contamination, incorrect concentration, injection-site reactions, and systemic exposure.

Long-term and theoretical concerns

Theoretical concerns include copper-related toxicity if systemic exposure meaningfully altered copper balance, although topical cosmetic use is not equivalent to systemic copper administration. No established drug-interaction framework for GHK-Cu was identified in approved labeling because there is no FDA-approved GHK-Cu drug label. Long-term safety data for chronic topical use are limited, and long-term human safety data for injectable use are inadequate for therapeutic claims.

Available through

Injectable GHK-Cu is not currently available through FDA-compliant prescription or compounding channels in the United States. ProPeptideGuide does not link to or endorse gray-market vendors, research-chemical sellers, or noncompliant injectable peptide sources^{[3 –6 ]}.

Topical cosmetic products containing Copper Tripeptide-1 are widely sold through ordinary cosmetic channels, but ProPeptideGuide does not evaluate or endorse specific cosmetic products on this page. Any product making claims to treat wounds, hair loss, inflammatory disease, scarring, or systemic aging may cross from cosmetic positioning into drug-claim territory under FDA’s intended-use framework^{[3 –4 ]}.